Multiple Myeloma

The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.

Latest News

Griffin: Daratumumab Plus RVd Improved Responses for Older and Some High-Risk Patients Compared With Triplet Alone in Newly Diagnosed MM
Griffin: Daratumumab Plus RVd Improved Responses for Older and Some High-Risk Patients Compared With Triplet Alone in Newly Diagnosed MM

January 29th 2023

The analysis, which was presented during the 64th ASH Annual Meeting and Exposition, highlighted stringent complete response data for patients 65 years and older and those with high cytogenic risk.

In Community-Based Study, Switching to Ixazomib in Newly Diagnosed MM Brought Improved Responses Across Age Groups
In Community-Based Study, Switching to Ixazomib in Newly Diagnosed MM Brought Improved Responses Across Age Groups

January 25th 2023

Study Finds Ixazomib Beneficial in MM Patients With High-Risk Cytogenic Traits
Study Finds Ixazomib Beneficial in MM Patients With High-Risk Cytogenic Traits

January 20th 2023

Disparities in Multiple Myeloma: Quality Improvement Initiative Reveals Gaps Between Oncology Providers, Patients in Views of Costs, Risk of Treatments
Disparities in Multiple Myeloma: Quality Improvement Initiative Reveals Gaps Between Oncology Providers, Patients in Views of Costs, Risk of Treatments

January 12th 2023

Spotlighting Health Disparities for Black Americans With Multiple Myeloma and Potential Solutions
Spotlighting Health Disparities for Black Americans With Multiple Myeloma and Potential Solutions

January 11th 2023

Video Interviews

More News

© 2023 MJH Life Sciences
AJMC®
All rights reserved.